Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Kidney Transplantation | Research article

Factors associated with adverse outcomes from cardiovascular events in the kidney transplant population: an analysis of national discharge data, hospital characteristics, and process measures

Authors: Amit K. Mathur, Yu-Hui Chang, D. Eric Steidley, Raymond L. Heilman, Nabil Wasif, David Etzioni, Kunam S. Reddy, Adyr A. Moss

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Kidney transplant (KT) patients presenting with cardiovascular (CVD) events are being managed increasingly in non-transplant facilities. We aimed to identify drivers of mortality and costs, including transplant hospital status.

Methods

Data from the 2009–2011 Nationwide Inpatient Sample, the American Hospital Association, and Hospital Compare were used to evaluate post-KT patients hospitalized for MI, CHF, stroke, cardiac arrest, dysrhythmia, and malignant hypertension. We used generalized estimating equations to identify clinical, structural, and process factors associated with risk-adjusted mortality and high cost hospitalization (HCH).

Results

Data on 7803 admissions were abstracted from 275 hospitals. Transplant hospitals had lower crude mortality (3.0% vs. 3.8%, p = 0.06), and higher un-adjusted total episodic costs (Median $33,271 vs. $28,022, p < 0.0001). After risk-adjusting for clinical, structural, and process factors, mortality predictors included: age, CVD burden, CV destination hospital, diagnostic cardiac catheterization without intervention (all, p < 0.001). Female sex, race, documented co-morbidities, and hospital teaching status were protective (all, p < 0.05). Transplant and non-transplant hospitals had similar risk-adjusted mortality. HCH was associated with: age, CVD burden, CV procedures, and staffing patterns. Hospitalizations at transplant facilities had 37% lower risk-adjusted odds of HCH. Cardiovascular process measures were not associated with adverse outcomes.

Conclusion

KT patients presenting with CVD events had similar risk-adjusted mortality at transplant and non-transplant hospitals, but high cost care was less likely in transplant hospitals. Transplant hospitals may provide better value in cardiovascular care for transplant patients. These data have significant implications for patients, transplant and non-transplant providers, and payers.
Literature
1.
go back to reference Bilancio G, Celano M, Cozza V, Zingone F, Palladino G, Cirillo M. Early prediction of cardiovascular disease in kidney transplant recipients. Transplant Proc. 2017;49(9):2092–8.CrossRef Bilancio G, Celano M, Cozza V, Zingone F, Palladino G, Cirillo M. Early prediction of cardiovascular disease in kidney transplant recipients. Transplant Proc. 2017;49(9):2092–8.CrossRef
2.
go back to reference Ballesteros F, Allard J, Durand C, Cardinal H, Lalonde L, Fortin MC. Kidney transplant Recipients' perspectives on cardiovascular disease and related risk factors after transplantation: a qualitative study. Transplant Direct. 2017;3(6):e162.CrossRef Ballesteros F, Allard J, Durand C, Cardinal H, Lalonde L, Fortin MC. Kidney transplant Recipients' perspectives on cardiovascular disease and related risk factors after transplantation: a qualitative study. Transplant Direct. 2017;3(6):e162.CrossRef
3.
go back to reference Kolonko A, Chudek J, Szotowska M, Kuczera P, Wiecek A. Cardiovascular risk factors and markers of atherosclerosis in stable kidney transplant recipients. Transplant Proc. 2016;48(5):1543–50.CrossRef Kolonko A, Chudek J, Szotowska M, Kuczera P, Wiecek A. Cardiovascular risk factors and markers of atherosclerosis in stable kidney transplant recipients. Transplant Proc. 2016;48(5):1543–50.CrossRef
4.
go back to reference Delville M, Sabbah L, Girard D, Elie C, Manceau S, Piketty M, et al. Prevalence and predictors of early cardiovascular events after kidney transplantation: evaluation of pre-transplant cardiovascular work-up. PLoS One. 2015;10(6):e0131237.CrossRef Delville M, Sabbah L, Girard D, Elie C, Manceau S, Piketty M, et al. Prevalence and predictors of early cardiovascular events after kidney transplantation: evaluation of pre-transplant cardiovascular work-up. PLoS One. 2015;10(6):e0131237.CrossRef
5.
go back to reference Mathur AK, Chang Y-H, Steidley DE, Heilman R, Khurmi N, Wasif N, et al. Patterns of care and outcomes in cardiovascular disease after kidney transplantation in the United States. Transplant Direct. 2017;3(2):e126.CrossRef Mathur AK, Chang Y-H, Steidley DE, Heilman R, Khurmi N, Wasif N, et al. Patterns of care and outcomes in cardiovascular disease after kidney transplantation in the United States. Transplant Direct. 2017;3(2):e126.CrossRef
6.
go back to reference Khurmi NS, Chang YH, Steidley DE, Singer AL, Hewitt WR, Reddy KS, Moss AA, Mathur AK. Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States. Liver Transpl. 2018;24(10):1398–410.CrossRef Khurmi NS, Chang YH, Steidley DE, Singer AL, Hewitt WR, Reddy KS, Moss AA, Mathur AK. Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States. Liver Transpl. 2018;24(10):1398–410.CrossRef
7.
go back to reference Lentine KL, Hurst FP, Jindal RM, Villines TC, Kunz JS, Yuan CM, et al. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis. 2010;55(1):152–67.CrossRef Lentine KL, Hurst FP, Jindal RM, Villines TC, Kunz JS, Yuan CM, et al. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis. 2010;55(1):152–67.CrossRef
8.
go back to reference Abbott KC, Bohen EM, Yuan CM, Yeo FE, Sawyers ES, Perkins RM, et al. Use of beta-blockers and aspirin after myocardial infarction by patient renal function in the Department of Defense health care system. Am J Kidney Dis. 2006;47(4):593–603.CrossRef Abbott KC, Bohen EM, Yuan CM, Yeo FE, Sawyers ES, Perkins RM, et al. Use of beta-blockers and aspirin after myocardial infarction by patient renal function in the Department of Defense health care system. Am J Kidney Dis. 2006;47(4):593–603.CrossRef
9.
go back to reference Lentine KL, Schnitzler MA, Brennan DC, Snyder JJ, Hauptman PJ, Abbott KC, et al. Cardiac evaluation before kidney transplantation: a practice patterns analysis in Medicare-insured dialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1115–24.CrossRef Lentine KL, Schnitzler MA, Brennan DC, Snyder JJ, Hauptman PJ, Abbott KC, et al. Cardiac evaluation before kidney transplantation: a practice patterns analysis in Medicare-insured dialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1115–24.CrossRef
10.
go back to reference Schnitzler MA, Salvalaggio PR, Axelrod DA, Lentine KL, Takemoto SK. Lack of interventional studies in renal transplant candidates with elevated cardiovascular risk. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2007;7(3):493–4.CrossRef Schnitzler MA, Salvalaggio PR, Axelrod DA, Lentine KL, Takemoto SK. Lack of interventional studies in renal transplant candidates with elevated cardiovascular risk. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2007;7(3):493–4.CrossRef
11.
go back to reference Agrawal S, Garg L, Garg A, Mohananey D, Jain A, Manda Y, et al. Recent trends in management and Inhospital outcomes of acute myocardial infarction in renal transplant recipients. Am J Cardiol. 2017;119(4):542–52.CrossRef Agrawal S, Garg L, Garg A, Mohananey D, Jain A, Manda Y, et al. Recent trends in management and Inhospital outcomes of acute myocardial infarction in renal transplant recipients. Am J Cardiol. 2017;119(4):542–52.CrossRef
12.
go back to reference Silber JH, Arriaga AF, Niknam BA, Hill AS, Ross RN, Romano PS. Failure-to-rescue after acute myocardial infarction. Med Care. 2018;56(5):416–23.PubMed Silber JH, Arriaga AF, Niknam BA, Hill AS, Ross RN, Romano PS. Failure-to-rescue after acute myocardial infarction. Med Care. 2018;56(5):416–23.PubMed
13.
go back to reference Mathur AK, Chang Y-H, Steidley DE, Katariya NN, Singer AL, Hewitt WR, et al. Hospitalizations for cardiovascular disease after kidney transplantation: the role of facility characteristics on outcomes and costs. Am J Transplant. 2016;16(S3):578. Mathur AK, Chang Y-H, Steidley DE, Katariya NN, Singer AL, Hewitt WR, et al. Hospitalizations for cardiovascular disease after kidney transplantation: the role of facility characteristics on outcomes and costs. Am J Transplant. 2016;16(S3):578.
14.
go back to reference Lentine KL, Schnitzler MA, Abbott KC, Bramesfeld K, Buchanan PM, Brennan DC. Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients. Clin J Am Soc Nephrol. 2009;4(7):1213–21.CrossRef Lentine KL, Schnitzler MA, Abbott KC, Bramesfeld K, Buchanan PM, Brennan DC. Sensitivity of billing claims for cardiovascular disease events among kidney transplant recipients. Clin J Am Soc Nephrol. 2009;4(7):1213–21.CrossRef
15.
go back to reference Ellimoottil C, Ye Z, Chakrabarti AK, Englesbe MJ, Miller DC, Wei JT, et al. Understanding inpatient cost variation in kidney transplantation: implications for payment reforms. Urology. 2016;87:88–94.CrossRef Ellimoottil C, Ye Z, Chakrabarti AK, Englesbe MJ, Miller DC, Wei JT, et al. Understanding inpatient cost variation in kidney transplantation: implications for payment reforms. Urology. 2016;87:88–94.CrossRef
16.
go back to reference Bureau of Economic Analysis, U.S. Department of Commerce. National Income and Product Accounts Table. In. http://www.bea.gov/iTable/iTable.cfm?reqid=9&step=3&isuri=1&903=13#reqid=9&step=3&isuri=1&903=13, 2016. Bureau of Economic Analysis, U.S. Department of Commerce. National Income and Product Accounts Table. In. http://​www.​bea.​gov/​iTable/​iTable.​cfm?​reqid=​9&​step=​3&​isuri=​1&​903=​13#reqid=9&step=3&isuri=1&903=13, 2016.
17.
go back to reference Liang KY, Zeger SL. Longitudinal data-analysis using generalized linear-models. Biometrika. 1986;73(1):13–22.CrossRef Liang KY, Zeger SL. Longitudinal data-analysis using generalized linear-models. Biometrika. 1986;73(1):13–22.CrossRef
18.
go back to reference Breiman L, Friedman JH, Stone CJ, Olshen RA. Classification and regression trees. Pacific Grove: Wadsworth; 1984. Breiman L, Friedman JH, Stone CJ, Olshen RA. Classification and regression trees. Pacific Grove: Wadsworth; 1984.
19.
go back to reference Pan W. Akaike’s information criterion in generalized estimating equations. Biometrics. 2001;57(1):120–5.CrossRef Pan W. Akaike’s information criterion in generalized estimating equations. Biometrics. 2001;57(1):120–5.CrossRef
20.
go back to reference Machnicki G, Lentine KL, Salvalaggio PR, Burroughs TE, Brennan DC, Schniztler MA. Three-year post-transplant Medicare payments in kidney transplant recipients: associations with pre-transplant comorbidities. Saudi J Kidney Dis Transpl. 2011;22(1):24–39.PubMed Machnicki G, Lentine KL, Salvalaggio PR, Burroughs TE, Brennan DC, Schniztler MA. Three-year post-transplant Medicare payments in kidney transplant recipients: associations with pre-transplant comorbidities. Saudi J Kidney Dis Transpl. 2011;22(1):24–39.PubMed
21.
go back to reference Xu X, Li SX, Lin H, Normand SL, Kim N, Ott LS, et al. “Phenotyping” hospital value of care for patients with heart failure. Health Serv Res. 2014;49(6):2000–16.PubMedPubMedCentral Xu X, Li SX, Lin H, Normand SL, Kim N, Ott LS, et al. “Phenotyping” hospital value of care for patients with heart failure. Health Serv Res. 2014;49(6):2000–16.PubMedPubMedCentral
22.
go back to reference Machnicki G, Pinsky B, Takemoto S, Balshaw R, Salvalaggio PR, Buchanan PM, et al. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Am J Transplant. 2009;9(3):494–505.CrossRef Machnicki G, Pinsky B, Takemoto S, Balshaw R, Salvalaggio PR, Buchanan PM, et al. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Am J Transplant. 2009;9(3):494–505.CrossRef
23.
go back to reference Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation. 2012;126(5):617–63.CrossRef Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation. 2012;126(5):617–63.CrossRef
24.
go back to reference Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transplant international : official journal of the European society for. Organ Transplant. 2015;28(1):10–21. Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transplant international : official journal of the European society for. Organ Transplant. 2015;28(1):10–21.
25.
go back to reference Lentine KL, Villines TC, Xiao H, Schnitzler MA, Brennan DC, Abbott KC, et al. Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation. 2011;91(10):1120–6.CrossRef Lentine KL, Villines TC, Xiao H, Schnitzler MA, Brennan DC, Abbott KC, et al. Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation. 2011;91(10):1120–6.CrossRef
26.
go back to reference Gaston RS, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(8):1811–5.CrossRef Gaston RS, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2009;9(8):1811–5.CrossRef
27.
go back to reference Dauerman HL, Bates ER, Kontos MC, Li S, Garvey JL, Henry TD, Manoukian SV, Roe MT. Nationwide Analysis of Patients With ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program. Circ Cardiovasc Interv. 2015;8(5):e002450. Dauerman HL, Bates ER, Kontos MC, Li S, Garvey JL, Henry TD, Manoukian SV, Roe MT. Nationwide Analysis of Patients With ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program. Circ Cardiovasc Interv. 2015;8(5):e002450.
28.
go back to reference Malik AO, Abela O, Allenback G, Devabhaktuni S, Lui C, Singh A, et al. ST-segment elevation myocardial infarction, systems of care. An urgent need for policies to co-ordinate care in order to decrease in-hospital mortality. Int J Cardiol. 2017. Malik AO, Abela O, Allenback G, Devabhaktuni S, Lui C, Singh A, et al. ST-segment elevation myocardial infarction, systems of care. An urgent need for policies to co-ordinate care in order to decrease in-hospital mortality. Int J Cardiol. 2017.
29.
go back to reference Patterson ME, Hernandez AF, Hammill BG, Fonarow GC, Peterson ED, Schulman KA, et al. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care. 2010;48(3):210–6.CrossRef Patterson ME, Hernandez AF, Hammill BG, Fonarow GC, Peterson ED, Schulman KA, et al. Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care. 2010;48(3):210–6.CrossRef
Metadata
Title
Factors associated with adverse outcomes from cardiovascular events in the kidney transplant population: an analysis of national discharge data, hospital characteristics, and process measures
Authors
Amit K. Mathur
Yu-Hui Chang
D. Eric Steidley
Raymond L. Heilman
Nabil Wasif
David Etzioni
Kunam S. Reddy
Adyr A. Moss
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1390-2

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.